ISSN: 0975-833X

*Available online at http://www.journalcra.com*

*International Journal of Current Research*
*Vol. 17, Issue, 10, pp.35115-35122, October, 2025*
*DOI: https://doi.org/10.24941/ijcr.49714.10.2025*

**INTERNATIONAL JOURNAL OF CURRENT RESEARCH**

# REVIEW ARTICLE

## AN UPDATED REVIEW ON BUPRENORPHINE AND METHADONE: EFFICACY, SAFETY AND CLINICAL INNOVATIONS

**Shivang Singh and *Anila Mishra**

Amity Institute of Pharmacy, Amity University Uttar Pradesh Lucknow Campus, Lucknow, Uttar Pradesh, India 226028

## ARTICLE INFO

***Article History:***
Received 24th July, 2025
Received in revised form
25th August, 2025
Accepted 17th September, 2025
Published online 30th October, 2025

***Keywords:***

Opioid Use Disorder (OUD), Buprenorphine, Methadone, Micro-Induction, Depot Formulations, transdermal Patches, Safety, Efficacy, clinical Advancements.

***Corresponding author:***
***Anila Mishra***

## ABSTRACT

Heroin, a semi-synthetic opioid derived from morphine, remains one of the most addictive and socially destructive substances worldwide. Its misuse contributes significantly to global morbidity, mortality and economic burden. The evolving understanding of opioid use disorder (OUD) has shifted its perception from moral failing to a complex neurobehavioral disease characterized by compulsive drug-seeking and neuroadaptive changes in brain circuits. Effective management of OUD relies on medication-assisted therapy (MAT), primarily involving buprenorphine and methadone, alongside psychosocial interventions. Buprenorphine, a partial μ-opioid receptor agonist and κ-opioid receptor antagonist, offers a unique therapeutic profile with a ceiling effect on respiratory depression, reducing overdose risks. Its transdermal, sublingual and depot formulations have improved adherence and minimized diversion potential. In contrast, methadone, a full μ-opioid receptor agonist and NMDA receptor antagonist, provides a stronger treatment retention and analgesic potency but demands careful titration due to cardiotoxicity and variable metabolism influenced by CYP polymorphisms. Recent advances in structure-activity relationship (SAR) studies, pharmacogenomics and green synthesis have expanded the therapeutic scope of both agents. Comparative analysis shows buprenorphine's superiority in safety and outpatient flexibility, while methadone remains indispensable for severe dependence. Future-oriented strategies such as micro-induction protocols, pharmacogenomics-guided dosing, digital adherence tools and integration of herbal adjuncts are reshaping OUD therapy into a more personalized and sustainable model. This review consolidates current evidence, pharmacological insights and translational innovations, underscoring how buprenorphine and methadone continue to redefine the landscape of addiction medicine.



***Citation: Shivang Singh and Anila Mishra. 2025.*** "An Updated Review on Buprenorphine and Methadone: Efficacy, Safety and Clinical Innovations.". *International Journal of Current Research, 17, (10), 35115-35122.*

# INTRODUCTION

The worldwide escalation of opioid use disorder (OUD) represents a critical public health challenge, resulting in increasing rates of morbidity, mortality and socioeconomic burden. Despite the in indispensable role of opioids in managing acute, chronic and palliative pain, their misuse has led to dependence and overdose-related deaths globally. The emerging recognition of OUD as a neurobehavioral disorder, rather than a moral failing, has shifted therapeutic potential towards evidence-based pharmacotherapies, notably buprenorphine and methadone. These agents form the foundation of medication-assisted treatment (MAT), each offering distinct pharmacodynamic and clinical attributes. Buprenorphine, a partial μ-opioid receptor agonist with κ-opioid receptor antagonism, exhibits ceiling effect that enhances safety and reduces overdose risks, while methadone, a full μ-opioid agonist and NMDA receptor antagonist, provides superior retention and analgesic strength but requires careful dosing due to its variable metabolism and cardiotoxic potential. This review therefore aims to critically analyze and compare the efficacy, safety and clinical innovations of buprenorphine and methadone, integrating both preclinical as well as clinical findings. The scope extends to exploring advancements in micro-induction protocols, depot and transdermal delivery systems, pharmacogenomic-guided dosing and green synthesis approaches, reflecting the transition towards safer and more personalized therapies. By consolidating mechanistic insights, formulation advances and translational applications, this review seeks to establish scientifically coherent framework for optimization of opioid agonist therapy and mitigating the global burden of OUD.

# METHODOLOGY

A comprehensive and Systematic literature review was conducted to meet the objectives of the review. The review followed a structured search strategy focusing on major scientific databases, including PubMed, Scopus, ScienceDirect and Google Scholar. The systematic exploration of data and publications included combinations of keywords such as "Opioid Use Disorder (OUD), Buprenorphine, Methadone, micro-induction, depot formulations, transdermal patches, efficacy, safety" and "clinical advancements". Both preclinical and clinical studies were included to provide a comprehensive understanding of the pharmacological profiles, therapeutic outcomes and safety aspects of the two agents. Articles were selected based on relevance, methodological quality and clarity

of experimental or clinical data. Mechanistic insights, pharmacokinetic properties, formulation trends and patient-centric innovations were critically examined. The collected literature was synthesized to develop a comparative and evidence-based perspective on how buprenorphine and methadone continue to evolve within the framework of addiction medicine.

Heroin also termed as diacetylmorphine and is a semi-synthetic derivative of morphine (1). It is known for its euphoric effects and is an addictive opioid (1). As per U.S. Department of Health and Human Services (HHS) opioid crisis was declared a public emergency in the year 2017 (2, 3). The heroin dependence is still a major health concern associated with mortality and morbidity which affects social aspects, productivity along with healthcare like HIV (Human immunodeficiency virus) as well as hepatitis C (4). ICD-10 (International Classification of Diseases tenth revision) code for heroin withdrawal classified opioid dependence with withdrawal (5). The management of opioid use disorder includes drugs like buprenorphine and methadone (6). Buprenorphine, a partial opioid agonist whereas methadone, a full opioid agonist addresses the significant issue of opioid use disorder (2). Methadone has an effective action in severe dependence and buprenorphine is safer, has ceiling effect and less overdose risk (7, 8).


**Figure 1. Effects of Heroin withdrawal**

The adjunct strategies are psychosocial support, relapse prevention (9). Opioids are a heterogeneous group of compounds that act primarily on opioid receptors—μ (mu), κ (kappa), and δ (delta)—to modulate pain, reward, and physiological processes (10). Their classification reflects chemical structure, source, and receptor activity. Despite being linked with dependency and overdose, opioids remain indispensable in medicine due to their unmatched analgesic efficacy and role in OUD (opioid use disorder) treatment (5, 11).




**Figure 3. Classification of opioids**




**Figure 4. Mechanism of action of Buprenorphine**

Opioids continue to offer various significant therapeutic benefits in modern medicine. They are considered as the gold standard for severe pain (acute, postoperative, cancer-related) due to their effective analgesic potential (12). In palliative and end-of-life care, opioids perform vital function in alleviating suffering in terminal illness (12). Additionally, they serve as valuable adjuncts in anesthesia protocols (8) as well as are potentially used in OUD therapy, drugs like methadone and buprenorphine reduce craving, withdrawal as well as illicit use (13). Furthermore, research frontiers the development of extended-release formulations, implants, transdermal delivery systems aimed for improving safety and compliance (14). However, besides its potent action opioids account for several opioid crisis. OUD is a condition that leads to development of a chronic condition which can be characterized by compulsive use of opioid drugs. More than 16 million people get affected from OUD worldwide (13). Despite ignoring their adverse consequences, for instance relapsing neurobehavioral condition which arise when an individual use these drugs for long time period. The criteria for defining OUD as per DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) which includes eleven symptoms related to recurrent use of opioids. An individual showing two or mere symptoms among the eleven DMS-5 criteria symptoms within 12- months span resulting in impairment and distress shall be defined under OUD (12). OUD can be diagnosed by several biomarkers including interleukin-10 (IL-10) which is a cytokine. Significantly higher expression of IL-10 were observed in patients with OUD (15). The risk factors associated with OUD are overdose and death due to respiratory suppression, tolerance and dependence (16). The management of OUD requires both medication for OUD as well as psychosocial treatment (17). The drugs involved in the pharmacotherapy are Methadone (full opioid agonist), Buprenorphine (a partial agonist) and Naltrexone (an opioid

antagonist) (18). These drugs are responsible for inhibiting the withdrawal symptoms thus, managing OUD along with the reversal of respiratory depression.

## INTRODUCTION TO BUPRENORPHINE

**Chemical Classification and Structure:** Buprenorphine is categorized as a semi-synthetic opioid and is structurally derived from thebaine (14), a naturally occurring alkaloid found in the opium poppy (19). It belongs to the phenanthrene group of opioids, which are recognized by their three-ring core (14). Chemically, it features significant modifications particularly the addition of a cyclopropylmethyl group at the nitrogen atom, which significantly affect its pharmacological profile (20). These structural changes allow it to function as a partial agonist at the mu- opioid receptor (MOR) (21) and as an antagonist at the kappa opioid receptor (KOR) and delta opioid receptor (DOR) receptors (22, 23). It also exhibits low-affinity activity at the nociceptin/orphanin FQ peptide (NOP) receptor (11). These complex interactions make buprenorphine distinct among opioids, both in its therapeutic effects and safety profile (18).

### Mechanism of Action

**Mu-opioid Receptor (MOR):** Buprenorphine binds to the MOR with high affinity but displays only partial activation (24). This enables it to reduce withdrawal symptoms and cravings in opioid-dependent individuals while minimizing euphoria and respiratory suppression state peals commonly seen with full agonists like heroin or fentanyl (11).

**Kappa and Delta Receptors:** Buprenorphine acts as an antagonist at KOR and DOR (25), preventing the dysphoric and hallucinogenic effects pain and therapy often triggered by their activation (11). This receptor profile is thought to contribute to its mood-stabilizing effects, especially beneficial for patients with co-occurring mental health disorders (14).

**Nociceptin Opioid Receptor (NOP):** Its weak partial agonism at the NOP receptor has limited clinical significance, but some studies suggest that it may fine-tune analgesic or affective responses without intensifying abuse potential same (14).

### Safety Profile and Ceiling Effect

One of buprenorphine's most notable advantages is its ceiling effect on respiratory depression and euphoria (5). Clinical data confirm that after a certain dose—usually around 4–8 mg— further increases do not proportionally increase adverse respiratory outcomes a modelling review. This makes buprenorphine a safer alternative to full opioid agonists, particularly in outpatient or high-risk populations (21). Studies in opioid-tolerant individuals demonstrate that high plasma levels of buprenorphine blunt the respiratory depressive effects of potent opioids like fentanyl. For instance, a significant reduction in fentanyl-induced respiratory suppression when steady-state buprenorphine was maintained above 2–3 ng/mL (26).

**Analgesic Potency and Efficacy:** Buprenorphine provides potent and sustained analgesia, particularly effective for moderate to severe chronic pain. Unlike its respiratory depressive effects, its analgesic benefits do not show a ceiling— meaning it can maintain effective pain control even at higher doses without escalating safety concerns (27). A 2023 meta-analysis published in Anesthesia & Analgesia confirmed that buprenorphine is non-inferior to morphine and oxycodone in pain management and causes fewer side effects like constipation, nausea, and sedation (28). It is particularly valuable for older adults and those with comorbidities where full agonists pose greater risk (29).

**Clinical Applications:** Buprenorphine is FDA (Food and Drug Administration)-approved for both pain management and the treatment of OUD (30). In the context of MAT, buprenorphine helps reduce cravings, blocks the euphoric effects of illicit opioids, and supports long-term recovery when paired with counseling and behavioral therapy (31).

### Structure-Activity Relationship of Buprenorphine




**Figur 5. Chemical Structure of Thebaine**




**Figure 6. Chemical Structure of Buprenorphine**

**Chemistry and Core Scaffold:** Buprenorphine derives from the oripavine/thebaine pathway via Diels–Alder cycloaddition to form the 6,14-endo-etheno bridge, followed by transformations to the orvinol scaffold. Its key features include: (i) a rigid 6,14-etheno bridge; (ii) a 3-phenolic hydroxyl; (iii) a 14- oxygen substituent; (iv) a bulky 7α tertiary alcohol side chain (≈ 2-hydroxy-3,3- dimethylbutan-2-yl); and (v) an N17- cyclopropylmethyl group. Modern syntheses proceed from oripavine or thebaine with improved N- demethylation/acylation protocols and green chemistry variants (32).

**Structural Determinants and SAR Map:** The most informative SAR (Structure Activity Relationship) positions and effects, integrating classical orvinol SAR with recent updates

**Synthesis of Buprenorphine:** Buprenorphine is synthesized from thebaine which is derived from opioid found in *Papaver somniferum* commonly called Opium Poppy.

**Theory: How Substitutions Shape Efficacy and Kinetics:** Efficacy at MOR in thebaine/buprenorphine arises from a balance of strong orthosteric binding and conformational constraints imposed by the 6,14-bridge and 7α side chain. Bulky N17 substituents (cyclopropylmethyl) favor partial agonism/antagonism by stabilizing receptor conformations with limited G- protein signaling, while slow dissociation kinetics contribute to prolonged receptor occupancy and the clinical 'ceiling' on respiratory depression. Extensions at 14-O and halogenation on the A-ring modulate secondary pocket interactions implicated in NOP cross-activity and signaling bias. Recent cryo- EM/biophysical work supports that buprenorphine's partial agonism results from submaximal stabilization of MOR active states and differential phosphorylation patterns, aligning with biased agonism observations. (7, 32).

**What's new beyond Earlier Reviews:** C(21)-fluorinated thevinol/orvinol scaffolds introduce strong inductive effects and metabolic stability, offering a fresh vector for tuning affinity and efficacy without heavy steric changes (32). Purpose-designed orvinol antagonists (e.g., compound 14) achieve naloxone-like reversal with potentially longer duration— useful for safety pharmacology and as probes. (21). C7β-methyl migration and related rearrangements deliver KOR antagonism with preserved high affinity and moderate NOP activity—expanding the antagonist space from orvinols (32). Emerging structural/biophysical insights (2025) attribute buprenorphine's partial and biased MOR agonism to distinct ligand-induced conformations—guiding next-gen orvinols with safer profiles (21).

**Clinical Relevance: Translating SAR to Practice:** Partial MOR agonism plus KOR antagonism underlie buprenorphine's analgesic and anti- craving benefits with a favorable safety ceiling (7, 12).

**Table 2. Derivatives and Clinical Variants of Methadone**

| Derivative/Enantiomer | IUPAC Name | Pharmacological action | Therapeutic Advantage | Ref. |
|---|---|---|---|---|
| Racemic Methadone | (RS)-6- (dimethylamino) -4,4- diphenylheptan- 3-one | Full μ-opioid receptor agonism | Standard clinical formulation for OUD and pain | (42,43) |
| Levomethadone (R- isomer) | R-(6- (dimethylamino)- 4,4- diphenylheptan-3- one) | Highμ- opioid selectivity, low NMDA antagonism | Lower cardiotoxicity potential | (38,44) |
| Dextromethadone (S- isomer) | S-(6- (dimethylamino)- 4,4- diphenylheptan- 3- one) | Potent N MDA antagonism, negligibleμ- opioid activity | Non-addictive analgesiaand antidepressant | (38,44) |

**Table 3:** Completed clinical interventions for Opioid Use Disorders

| Sr. No. | NCT No. | Interventions | Sponsors | Ref. |
|---|---|---|---|---|
| 1. | NCT03205423 | Gabapentin | New York State Psychiatric Institute in the Division on Substance Use Disorders, New York, New York, United States | (49) |
| 2. | NCT05053503 | Lofexidine | Spark Biomedical, Inc. | (50) |
| 3. | NCT04716881 | Naltrexone | Go Medical Industries Pty Ltd. Columbia University Medical Center, New York, New York, United States | (51) |
| 4. | NCT04818086 | Lemborexant | Virginia Commonwealth University, Richmond, Virginia,United States | (52) |
| 5 . | NCT05447286 | Oxycodone | The Yale Stress Center: Yale University, New Haven, Connecticut, United States | (53) |

**Table 4:** Ongoing clinical interventions for Opioid Use Disorders

| Sr. No. | NCT No. | Interventions | Sponsors | Ref. |
|---|---|---|---|---|
| 1. | NCT06067737 | Psilocybin | Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland, United States | (54) |
| 2. | NCT05063201 | Cariprazine | Kyle Kampman, University of | (55) |
| | | | Pennsylvania, Philadelphia, | |
| 3. | NCT06639464 | Semaglutide | Brigham and Women's Hospital, Boston, Massachusetts, United States | (56) |
| 4. | NCT03958474 | Remifentanil | Joshua A. Lile, Ph.D., Laboratory of HumanBehavioral Pharmacology, Lexington, Kentucky, United States | (57) |
| 5. | NCT06642181 | Guanfacine | Rutgers School of Health Professions,Newark, New Jersey, United States | (58) |




**Figure 7. Synthesis of Buprenorphine**




**Figure 8. Mechanism of action of Methadone**

Formulation advances (transdermal, buccal, extended- release) leverage its slow off-rate and high affinity. Novel SAR directions (isotopic substitution, halogenation, 14-O extensions, orvinol antagonists) may refine respiratory safety, reduce tolerance, and tailor NOP engagement (12, 32).

**Rationale for Buprenorphine Formulation Withdrawal and Regulatory Restrictions**

Despite being widely used, buprenorphine formulations have occasionally faced market withdrawal or restricted use due to clinical, pharmacological, and regulatory concerns. The key factors include:

- Partial Agonist Activity and Precipitated Withdrawal – Buprenorphine exhibits very high μ- opioid receptor affinity but only partial agonist activity, which may precipitate withdrawal when administered (29).
- Ceiling Effect on Analgesia – The intrinsic safety advantage of buprenorphine is its ceiling effect for respiratory depression, but this also limits its use in managing severe pain, making it less suitable for some patients with co-existing pain syndromes (7).
- Diversion and Abuse Potential – Sublingual buprenorphine tablets and films have been reported to be diverted, injected, or sold in illicit markets, prompting regulators to enforce tighter controls and even withdraw certain products in regions with high misuse rates (7).
- Drug–Drug Interactions and Safety Risks – Buprenorphine is primarily metabolized via CYP3A4, raising the potential for significant interactions with inhibitors such as azole antifungals or macrolides. Co-administration with benzodiazepines has been implicated in fatal overdoses (14).
- Formulation-Specific Challenges – Some transdermal products have faced issues such as poor patch adhesion, skin reactions, or inconsistent bioavailability (33), which contributed to their discontinuation in certain markets (27). Moreover, the oral bioavailability of buprenorphine remains very low (~15%) (7).

**Transdermal Patches Remain a Focus of Research:** Despite some withdrawals, transdermal buprenorphine patches remain an attractive alternative due to their ability to deliver steady plasma levels, reducing peak-trough fluctuations and minimizing breakthrough withdrawal or craving. These patches are harder to misuse compared with sublingual tablets (cannot be easily injected), and they improve patient adherence by reducing dosing frequency. Ongoing studies are investigating abuse-deterrent adhesives, flexible titration schedules, and co-formulations with naloxone to further enhance safety (34).

**Efficacy and Safety: Current Evidence and Challenges**

Both buprenorphine and methadone significantly reduce opioid-related mortality, illicit opioid use, and improve treatment retention compared with no medication-assisted treatment (MAT) (13). Buprenorphine/naloxone combinations are particularly effective in outpatient settings and have demonstrated good tolerability (12).
Key safety concerns include precipitated withdrawal during induction if patients are not in adequate spontaneous withdrawal prior to dosing. Plasma level fluctuations from sublingual dosing can contribute to breakthrough cravings and potential relapse. Other safety concerns include risk of diversion, overdose (especially with sedative co-use), and variable adherence (12).

**Innovations are focusing on:**

- Low-Dose/Micro-Induction Protocols: Gradual receptor occupancy reduces the likelihood of precipitated withdrawal (35).
- Patch Bridging Strategies: Using low-dose transdermal patches before sublingual initiation has shown success in hospitalized patients with minimal withdrawal symptoms (34).
- Depot/Extended-Release Injections: Provide consistent plasma levels for weeks, improves adherence and reduced diversion risk (35).

**Case Studies and Clinical Evidence**

Several clinical reports have demonstrated the feasibility of rapid transdermal induction to extended-release buprenorphine in inpatient settings, with only mild withdrawal symptoms reported (34). A retrospective cohort study involving 32 patients transitioning from full agonists to buprenorphine using patches found that 92.6% successfully completed induction, with good or fair tolerability in >90% of cases (35). A systematic review of 22 studies on rotation from chronic opioid therapy to buprenorphine confirmed reductions in pain, acceptable tolerability, and low incidence of precipitated withdrawal, though evidence quality was limited by study heterogeneity (3).

**Methadone:** Methadone is a synthetic diphenylheptane opioid that has held a central place in clinical medicine for over seven decades, originally developed in Germany in the late 1930s and entering practice in the 1940s as a synthetic alternative to morphine for analgesia (36). Over time, its pharmacological profile marked by a long half-life, robust oral bioavailability, and potent μ-opioid receptor activity secured its use for chronic pain management and opioid use disorder (OUD) therapy (37). In addition, methadone's flexible chemical framework and its dual action, including NMDA (N-methyl-D-aspartate) receptor antagonism, have made it a focus in both research and clinical innovation (8). Medicinal chemistry marks methadone as unique among opioids due to its acyclic diphenylpropylamine backbone, which contrasts with the rigid polycyclic structure of morphine. Its IUPAC name is (RS)-6-(dimethylamino)-4,4-diphenylheptan-3-onehints at its flexible structure, composed of a

tertiary amine, a central ketone, and two phenyl rings (38). This arrangement allows the molecule to adopt multiple conformations, mimicking the opioid pharmacophore necessary for potent μ-opioid receptor binding (38). The compound has a single chiral center, yielding two enantiomers: R-methadone (levomethadone), responsible for classical opioid effects, and S- methadone (dextromethadone), which is primarily an NMDA receptor antagonist with limited opioid activity (38).Pharmacologically, methadone stands out with its high oral bioavailability (41–99%), extensive protein binding (>90%), and a variable half-life that can extend up to 190 hours in some individuals (8). Metabolism is chiefly through hepatic CYP (Cytochrome P450) enzymes—especially CYP3A4, CYP2B6, and CYP2D6— which, through genetic polymorphism, create marked individual differences in drug levels and effects, driving the need for precision dosing and the application of pharmacogenetic testing (8). From a clinical innovation standpoint, advances have included stereoselective and "green chemistry" synthesis (39), the development of enantiomer-pure drugs for improved safety, and evolving protocols for OUD and pain therapy. Methadone's NMDA antagonism and low propensity for opioid tolerance broaden its applications and inspire research into new derivatives for pain and psychiatry (40).

**Structural Chemistry and SAR:** Methadone's pharmacological role is closely related to its structure-activity relationship (SAR). The two phenyl rings and the dimethylamino side chain facilitate alignment for MOR binding, while the central ketone gives conformational flexibility. SAR studies highlight that the R-enantiomer is significantly more potent at MOR due to optimal stereoelectronic fit, while the S-enantiomer primarily interacts with NMDA receptors, holding potential as a non- addictive analgesic and antidepressant agent (41). Methadone shows its pharmacological action primarily through potent agonism at the μ-opioid receptor (MOR), producing analgesia and respiratory depression. Its high intrinsic efficacy at MOR suppresses opioid cravings and withdrawal in individuals with opioid dependence (37). Modern synthetic approaches emphasize stereoselective synthesis and green chemistry to optimize enantiomeric purity, reduce waste, and improve scalability. Such synthetic innovations have made methadone not only a clinical staple but also a valuable template in medicinal chemistry discovery (39).




**Figure 9. Chemical Structure of Methadone**

**Synthesis of Methadone**




**Figure. 10 Synthesis of Methadone**

**Pharmacokinetics**: Methadone's physicochemical properties—high lipophilicity and protein binding—aid in its broad tissue distribution and decrease detoxification rates, which contribute to stable plasma concentrations during maintenance therapy (8). Its elimination half-life is highly variable, requiring slow and careful titration to avoid accidental toxicity, with most elimination occurring via hepatic metabolism and subsequent urinary and fecal excretion (8).

**Dosage and Therapeutic Use:** Initiation for OUD typically begins at 20–30 mg/day orally, with maintenance usually at 60– 120 mg/day and doses adjusted based on withdrawal symptom control and the risk of toxicity (45). Chronic pain treatment starts at lower doses, often 2.5–10 mg every 8–12 hours, and is titrated according to patient needs (45). Clinical guidance increasingly recommends pharmacogenetic screening for CYP variants to optimize safety and efficacy (46).

**Adverse Effects:** Common side effects of methadone include constipation, sedation, and sweating; serious risks comprise respiratory depression, QT interval prolongation and torsades de pointes (47). Hepatic monitoring is warranted, particularly in patients at risk of liver dysfunction (48).

**Clinical Innovation and Future Directions:** Research continues to focus on refining enantiomer-selective therapies, creating more environmentally sustainable production processes, and leveraging pharmacogenomics to improve clinical safety. Methadone's NMDA antagonism is being exploited for novel indications, including mood disorders and complex pain syndromes (8). The horizon for methadone thus links molecular innovation, clinical flexibility, and personalized medicine. Buprenorphine and Methadone: Global Burden, Comparative Efficacy, Safety and Pharmacokinetics

**Global Burden and Socioeconomic Impact:** According to the WHO (World Health Organization), more than 16 million people globally suffer from OUD, with North America reporting the highest prevalence of overdose deaths (13). In 2022, more than 80,000 opioid-related fatalities were recorded in the United States alone, highlighting the crisis severity (59). Despite the availability of medications, around 90% of individuals do not receive the treatment (15).

**Comparative Efficacy of Methadone and Buprenorphine**

- **Clinical Outcomes:** Buprenorphine's partial agonist activity and ceiling effect on respiratory depression confer safety advantages in outpatient settings, whereas methadone, with its full agonist profile, provides stronger retention but requires intensive supervision (11).
- **Special Populations:** Pregnant women on buprenorphine show lower incidence of neonatal abstinence syndrome compared to methadone, while adolescents and patients with psychiatric comorbidities also appear to benefit from buprenorphine's mood-stabilizing properties (2).

**Safety Profiles and Adverse Effects**

- **Buprenorphine:** Its ceiling effect reduces overdose risk, but challenges include precipitated withdrawal when administered too soon after full agonists, potential diversion (6, 22) Norbuprenorphine, its active metabolite, has limited central nervous system penetration, further reducing overdose potential (14).
- **Methadone:** High variability in half-life, absence of a ceiling effect, and full μ- agonism increase overdose risk, particularly in the induction phase (18). Methadone is also strongly associated with QTc prolongation, with up to 15% of patients showing prolongation (47).
- **Comparative Mortality:** Buprenorphine is associated with lower rates of mortality as compared to methadone even in pregnant women (60).

**Conclusion and Future Innovations**

This review highlights the pivotal role of buprenorphine and methadone in the management of opioid use disorder (OUD) and chronic pain, emphasizing their pharmacological uniqueness, clinical applications, and ongoing innovations. Both agents remain central to evidence-based treatment strategies, yet their differences in efficacy, safety, and pharmacokinetics allow for individualized patient care.

Buprenorphine's partial agonism and ceiling effect on respiratory depression make it a safer option in outpatient and high- risk populations, while methadone's full agonist activity provides strong retention benefits but requires careful monitoring due to variability in metabolism and cardiotoxic risks. Beyond their established clinical roles, recent advances in structural chemistry, stereoselective synthesis, and pharmacogenomic insights have reshaped the therapeutic landscape, paving the way for more precise and patient-centered interventions. Innovations such as micro-induction protocols, depot injections, and transdermal systems demonstrate progress toward reducing induction challenges, improving adherence, and limiting diversion. The integration of complementary approaches, including herbal agents like crocin and digital health support, further expands the potential for holistic and sustainable care models. At a public health level, the burden of OUD remains profound, with rising overdose deaths and significant socioeconomic costs underscoring the urgency of expanding access to these therapies. Global disparities in treatment availability highlight the need for policy reforms, education, and broader implementation of opioid agonist therapies. Future directions demand pharmacogenomic-guided methadone dosing to reduce cardiotoxicity, and the expansion of depot or extended-release buprenorphine to enhance adherence. Emerging evidence also supports micro-dosing induction protocols that prevent precipitated withdrawal and facilitate smoother transitions from full agonists. The integration of digital adherence monitoring, abuse-deterrent formulations, and telehealth-based supervision promises a scalable, patient-centered approach to MAT.

At the molecular level, structural chemistry advancements—including isotopic substitution, C21-fluorination, and orvinol antagonists—offer potential for safer, bias- selective opioid ligands. Concurrently, green synthesis and enantiomeric purification of methadone contribute to more sustainable and precise pharmacotherapy. Holistic strategies are gaining ground, merging pharmacotherapy with psychosocial counseling, mindfulness, and herbal adjuvants such as crocin, which may alleviate withdrawal-related oxidative and inflammatory stress. Such integrative models emphasize the biopsychosocial nature of addiction, promoting recovery beyond mere abstinence. From a public health standpoint, equitable access remains a critical challenge—only a fraction of those affected by OUD receive MAT globally. Expanding harm-reduction policies, reducing regulatory barriers, and destigmatizing opioid agonist therapy are essential. In conclusion, buprenorphine and methadone represent more than substitution therapies— they are dynamic pillars of modern addiction medicine. Their continued refinement through pharmacological, genetic, and digital innovation holds promise for a future where OUD management is safer, more equitable, and deeply personalized. This paradigm shift— from crisis management to recovery-oriented care—marks a significant step toward mitigating the global opioid epidemic.

**Conflict of Interest:** No conflict of interest.

# REFERENCES


1. Milella MS, D'Ottavio G, De Pirro S, Barra M, Caprioli D, Badiani A. Heroin and its metabolites: relevance to heroin use disorder. Translational Psychiatry. 2023;13(1):120.
2. Bell J, Strang J. Medication Treatment of Opioid Use Disorder. Biol Psychiatry. 2020;87(1):82-8.
3. Hodge Jr JG, Wetter SA, Chronister D, Hess A, Piatt JJJ. Redefining public health emergencies: The opioid epidemic. 2017:1-15.
4. Aldridge RW, Story A, Hwang SW, Nordentoft M, Luchenski SA, Hartwell G, *et al*. Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis. 2018;391(10117):241-50.
5. Fipps DC, Oesterle TS, Kolla BP, editors. Opioid maintenance therapy: A review of methadone, buprenorphine, and naltrexone treatments for opioid use disorder. Seminars in neurology; 2024: Thieme Medical Publishers, Inc.
6. Hurley RW, Bland KT, Chaskes MD, Hill EL, Adams MCJPM. Diagnosis and coding of opioid misuse: a systematic scoping review and implementation framework. 2025:pnaf019.
7. Infantino R, Mattia C, Locarini P, Pastore AL, Maione S, Luongo LJB. Buprenorphine: far beyond the "ceiling". 2021;11(6):816.
8. Hanna V, Senderovich HJTjop. Methadone in pain management: a systematic review. 2021;22(3):233-45.
9. Zweben JE, Sorensen JL, Shingle M, Blazes CKJJoam. Discontinuing methadone and buprenorphine: a review and clinical challenges. 2021;15(6):454-60.
10. Davis MJD. Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits. 2025;85(2):215-30.
11. Coe MA, Lofwall MR, Walsh SL. Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. J Addict Med. 2019;13(2):93-103.
12. Kim EJ, Hwang EJ, Yoo YM, Kim KH. Prevention, diagnosis, and treatment of opioid use disorder under the supervision of opioid stewardship programs: it's time to act now. The Korean journal of pain. 2022;35(4):361-82.
13. Wakeman SEJNe. Opioid use disorder diagnosis and management. 2022;1(4):EVIDra2200038.
14. Pande LJ, Arnet RE, Piper BJJP. An examination of the complex pharmacological properties of the non-selective opioid modulator buprenorphine. 2023;16(10):1397.
15. Bryant BM, Eaton E, Li LJFiP. A systematic review of opioid use disorder and related biomarkers. 2021;12:708283.
16. Webster LRJA, analgesia. Risk factors for opioid-use disorder and overdose. 2017;125(5):1741-8.
17. Hoffman KA, Ponce Terashima J, McCarty DJBhsr. Opioid use disorder and treatment: challenges and opportunities. 2019;19(1):884.
18. Degenhardt L, Clark B, Macpherson G, Leppan O, Nielsen S, Zahra E, *et al*. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. The Lancet Psychiatry. 2023;10(6):386-402.
19. Dydyk A, Jain N, Gupta M. Opioid Use Disorder: Evaluation and Management. StatPearls; StatPearls Publishing: Treasure Island, FL, USA. 2025.
20. Lutfy K, Cowan AJCn. Buprenorphine: a unique drug with complex pharmacology. 2004;2(4):395-402.
21. Baldo BAJAJoP-LC, Physiology M. Opioid-induced respiratory depression: clinical aspects and pathophysiology of the respiratory network effects. 2025;328(2):L267-L89.
22. Guerrero M, Urbano M, Kim E-K, Gamo AM, Riley S, Abgaryan L, *et al*. Design and synthesis of a novel and selective kappa opioid receptor (KOR) antagonist (BTRX-335140). ACS Publications; 2019.
23. Burgess G, Amin S, Jutkiewicz EJTFJ. Delta Opioid Receptor (DOR) Agonist Activity of Buprenorphine in Mice. 2021;35.
24. Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain and therapy. 2020;9(1):41-54.
25. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical pharmacokinetics. 2005;44(7):661-80.
26. Van der Schrier R, Dahan JD, Boon M, Sarton E, van Velzen M, Niesters M, *et al*. Advances in reversal strategies of opioid-induced respiratory toxicity. 2022;136(4):618-32.
27. Powell VD, Rosenberg JM, Yaganti A, Garpestad C, Lagisetty P, Shannon C, *et al*. Evaluation of buprenorphine rotation in patients receiving long-term opioids for chronic pain: a systematic review. 2021;4(9):e2124152-e.
28. Hickey TR, Costa GP, Oliveira D, Podosek A, Abelleira A, Avila-Quintero VJ, *et al*. Buprenorphine versus full agonist opioids for acute postoperative pain management: a systematic review and meta-analysis of randomized controlled trials. 2025.

29. Dalal S, Chitneni A, Berger AA, Orhurhu V, Dar B, Kramer B, *et al*. Buprenorphine for chronic pain: a safer alternative to traditional opioids. 2021;9(1):27241.
30. Vu PD, Bansal V, Chitneni A, Robinson CL, Viswanath O, Urits I, *et al*. Buprenorphine for chronic pain management: a narrative review. 2023;27(12):811-20.
31. Ghanem N, Dromgoole D, Hussein A, Jermyn RTJJoom. Review of medication- assisted treatment for opioid use disorder. 2022;122(7):367-74.
32. Kyzer JL, Wenthur CJJAcn. Classics in chemical neuroscience: buprenorphine. 2020;11(10):1385-99.
33. Coe MA, Lofwall MR, Walsh SL. Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. Journal of addiction medicine. 2019;13(2):93- 103.
34. Dhawan A, Modak T, Sarkar SJAJoP. Transdermal buprenorphine patch: potential for role in management of opioid dependence. 2019;40:88-91.
35. Naren T, Cook J, MacCartney P, Membrey D. Buprenorphine microdosing regimen using transdermal buprenorphine patches to transition from methadone to buprenorphine. Drug and alcohol review. 2024;43(4):1013-8.
36. Chona K. Methadone and its usage in treatment of opioid drug addiction. 2017.
37. Coluzzi F, Rullo L, Scerpa MS, Losapio LM, Rocco M, Billeci D, *et al*. Current and future therapeutic options in pain management: multi-mechanistic opioids involving both MOR and NOP receptor activation. 2022;36(6):617-32.
38. Banzato M, Furlan A, Locatelli P, Sgrignani J, Ongaro A, Dolmella A, *et al*. New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (R)- and (S)-Methadone Metabolites as N-Methyl-d-aspartate Receptor Antagonists. J Med Chem. 2025;68(5):5455- 70.
39. Kar S, Sanderson H, Roy K, Benfenati E, Leszczynski JJCR. Green chemistry in the synthesis of pharmaceuticals. 2021;122(3):3637-710.
40. Bernstein G, Davis K, Mills C, Wang L, McDonnell M, Oldenhof J, *et al*. Characterization of the Safety and Pharmacokinetic Profile of D-Methadone, a Novel N- Methyl-D-Aspartate Receptor Antagonist in Healthy, Opioid-Naive Subjects: Results of Two Phase 1 Studies. Journal of clinical psychopharmacology. 2019;39(3):226-37.
41. Michaelides M, Levinstein M, De Oliveira P, Casajuana-Martin N, Quiroz C, Budinich R, *et al*. Unique pharmacodynamic properties and low abuse liability of the μ- opioid receptor ligand (S)-methadone. Research square. 2023.
42. Brown P, Ryder A, Robinson C, Valenti K, Phung K, Hasoon J. Methadone for Chronic Pain: A Review of Pharmacology, Efficacy, and Safety Concerns. Health Psychol Res. 2025;13:129552.
43. Levinstein MR, De Oliveira PA, Casajuana-Martin N, Quiroz C, Budinich RC, Rais R, *et al*. Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone. Molecular psychiatry. 2024;29(3):624-32.
44. Chalabianloo F, Fadnes LT, Johansson KA, Høiseth G, Vold JH, Kringen MK, *et al*. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Basic & Clinical Pharmacology & Toxicology. 2024;134(3):333-44.
45. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. Journal of addiction medicine. 2015;9(5):358-67.
46. Eum S, Vernacchia NP, Doughty N, Mehrzad S, Talal AH, Chalabianloo F, *et al*. Methadone metabolism and cytochrome P450 polymorphisms: a systematic review and meta- analysis. 2025;21(3):289-304.
47. Titus-Lay EN, Jaynes HA, Tomaselli Muensterman E, Walroth TA, Ott CA, Desta Z, *et al*. Methadone-associated QT interval prolongation in patients undergoing maintenance therapy in an urban opioid treatment program. 2021;41(3):238-46.
48. Ključević Ž, Benzon B, Ključević N, Veršić Bratinčević M, Sutlović D. Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-sectional study. Croatian medical journal. 2018;59(6):298-306.
49. Medicine NLo. Medication Development for Opioid and Alcohol Abuse 2024 [Available from: https://clinicaltrials.gov/study/NCT03205423?cond=Opioid%20Use%20Disorder&term=dru gs&rank=61.
50. Medicine NLo. Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder (RESTORE) 2025 [Available from: https://clinicaltrials.gov/study/NCT05053503?cond=Opioid%20Use%20Disorder&term=dru gs&page=2&rank=156.
51. Medicine NLo. Pharmacokinetic Study of Vivitrol in Healthy Participants 2024 [Available from: https://clinicaltrials.gov/study/NCT04716881?cond=Opioid%20Use%20Disorder&term=dru gs&page=2&rank=174.
52. Medicine NLo. Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder 2024 [Available from: https://clinicaltrials.gov/study/NCT04818086?cond=Opioid%20Use%20Disorder&term=dru gs&page=3&rank=243.
53. Medicine NLo. Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study 2025 [Available from: https://clinicaltrials.gov/study/NCT05447286?cond=Opioid%20Use%20Disorder&term=dru gs&page=3&rank=244.
54. Medicine NLo. Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder (BIPOD-Out) 2025 [Available from: https://clinicaltrials.gov/study/NCT06067737?cond=Opioid%20Use%20Disorder&term=dru gs&aggFilters=phase:3%201%202%200,status:rec&rank=18.
55. Medicine NLo. Cariprazine for Comorbid Cocaine and Opioid Use Disorder 2025 [Available from: https://clinicaltrials.gov/study/NCT05063201?cond=Opioid%20Use%20Disorder&term=dru gs&aggFilters=phase:3%201%202%200,status:rec&rank=22.
56. Medicine NLo. Semaglutide for Helping Opioid Recovery (SHORE) 2025 [Available from: https://clinicaltrials.gov/study/NCT06639464?cond=Opioid%20Use%20Disorder&term=dru gs&aggFilters=phase:3%201%202%200,status:rec&rank=35.
57. Medicine NLo. Neurobehavioral Mechanisms of Choice in Opioid Use Disorder 2025 [Available from: https://clinicaltrials.gov/study/NCT03958474?cond=Opioid%20Use%20Disorder&term=dru gs&aggFilters=phase:3%201%202%200,status:rec&rank=39.
58. Medicine NLo. Combined Guanfacine and Mindfulness Meditation as an Adjunct to Buprenorphine Maintenance in Opioid Use Disorder 2025 [Available from: https://clinicaltrials.gov/study/NCT06642181?cond=Opioid%20Use%20Disorder&term=dru gs&aggFilters=phase:3%201%202%200,status:rec&rank=48.
59. Brandeau MLJHcms. Responding to the US opioid crisis: leveraging analytics to support decision making. 2023;26(4):599-603.
60. Gottlieb DJ, Shiner B, Hoyt JE, Riblet NB, Peltzman T, Teja N, *et al*. A comparison of mortality rates for buprenorphine versus methadone treatments for opioid use disorder. 2023;147(1):6-15.


*******